DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Summary for human papillomavirus 9-valent vaccine, recombinant
|Suppliers: see list||1|
|Recent Clinical Trials:||See clinical trials for human papillomavirus 9-valent vaccine, recombinant|
Recent Clinical Trials for human papillomavirus 9-valent vaccine, recombinant
Identify potential brand extensions & biosimilar entrants
|Merck Sharp & Dohme Corp.||Phase 3|
|Merck Sharp & Dohme Corp.||Phase 1|
|University Health Network, Toronto||Phase 1|
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Patent Text Search
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Merck Sharp & Dohme Corp.||GARDASIL 9||human papillomavirus 9-valent vaccine, recombinant||INJECTION, SUSPENSION||125508||2014-12-10||⤷ Try it Free||Marbley; Theodore C. (Palm Springs, CA)||2035-07-21||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|30/2001||Austria||⤷ Try it Free||PRODUCT NAME: RECOMBINANTES HUMANES OSTEOGENES PROTEIN-1 (OP 1)|
|C/GB10/043||United Kingdom||⤷ Try it Free||PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR))(HUMAN MONOCLONAL AMG 162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG 162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100526; UK EU/1/10/618/002 20100526; UK EU/1/10/618/003 20100526; UK EU/1/10/618/004 20100526|
|C/GB96/011||United Kingdom||⤷ Try it Free||PRODUCT NAME: RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE; REGISTERED: FI 11529 19940815; FI 11530 19940815; UK EU/1/95/001 19951020; UK EU/1/95/002 19951020; UK EU/1/95/003 19951020; UK EU/1/95/004 19951020; UK EU/1/95/005 19951020; UK EU/1/95/006 19951020; UK EU/1/95/007 19951020; UK EU/1/95/008 19951020; UK EU/1/95/009 19951020; UK EU/1/95/010 19951020; UK EU/1/95/011 19951020; UK EU/1/95/012 19951020; UK EU/1/95/013 19951020; UK EU/1/95/014 19951020; UK EU/1/95/015 19951020; UK EU/1/95/016 19951020|
|C/GB10/044||United Kingdom||⤷ Try it Free||PRODUCT NAME: DENOSUMAB, IMMUNOGLOBULIN G2, ANTI-(HUMAN TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 11 (HUMAN OSTEOCLAST DIFFERENTIATION FACTOR)) HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER.; REGISTERED: UK EU/1/10/618/001 20100528; UK EU/1/10/618/002 20100528; UK EU/1/10/618/003 20100528; UK EU/1/10/618/004 20100528|
|>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.